Loading
A phase 3 trial of Cadonilimab, Lenvatinib in hepatocellular carcinoma, run by Akeso, now recruiting.
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT06371157 by Akeso, with 469 participants planned, started 2024-08-02 and due to reach its primary completion in 2025-10-25. Interventions recorded: AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cadonilimab, Akeso, Bispecific antibodies, Hepatocellular carcinoma.
Shares Cadonilimab, Akeso, Bispecific antibodies, Hepatocellular carcinoma.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Intermediate hepatocellular carcinoma (BCLC B), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Akeso, Bispecific antibodies, Anti-angiogenic therapy, Immune checkpoint inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/